Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949830 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
A Phase 1 study of Acute Intermittent Porphyria, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 5
- Study locations
NCT02949830 is a Phase 1 study of Acute Intermittent Porphyria that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 16 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT02949830, a Phase 1 study of Acute Intermittent Porphyria, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients who completed study ALN-AS1-001 (NCT02452372).
Conditions Studied
Interventions
- DRUG Givosiran
Study Locations (5)
Other
- Clinical Trial Site - Stockholm
- Clinical Trial Site - London
California
- Clinical Trial Site - San Francisco
New York
- Clinical Trial Site - New York
Texas
- Clinical Trial Site - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02949830
The ClinicalTrials.gov registry entry for NCT02949830 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Intermittent Porphyria appearing as the primary indexed condition, and to 1 intervention - of which Givosiran is the first listed.
NCT02949830 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT02949830 about?
NCT02949830 is a clinical study titled "A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)". The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients who completed study ALN-AS1-001 (NCT02452372).
What is the current status of trial NCT02949830?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-10. Estimated completion is 2021-11-05.
What conditions does trial NCT02949830 study?
This clinical trial studies the following conditions: Acute Intermittent Porphyria.
What interventions are being tested in trial NCT02949830?
The interventions under investigation include: Givosiran (DRUG).
Who is sponsoring clinical trial NCT02949830?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02949830 being conducted?
This trial has 5 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Intermittent Porphyria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.